UCB to acquire Ra Pharmaceuticals for $2.1B
Belgian drug plastics group UCB has agreed to buy United States-based clinical-stage company Ra Pharmaceuticals for $2.1 billion, the companies said. The deal will allow UCB to offer new immunology and neurology treatments for several rare diseases. UCB CEO Jean-Christophe Tellier highlighted that Ra Pharma is an excellent strategic fit in multiple areas of UCB’s […]
